CREATE
TRANSFORMATIVE
MEDICINES
TRANSFORMATIVE
MEDICINES
A global leader in innovative solutions for the discovery, development, and manufacture of novel nanoparticle medicines.
Workshop & Livestream Event:
Advances in mRNA Vaccine Therapies
Advances in mRNA Vaccine Therapies in the Fields of Cancer Immunotherapy and Infectious Diseases
Dr. Richner's research is on the emergence of Zika virus (ZIKV) infection has prompted a global effort to develop safe and effective vaccines. Recent technological advances have led to a number of promising vaccine platforms including antigen-coding mRNA vaccines encapsidated in a lipid nanoparticle (mRNA-LNP). Dr. Perrie's research is multi-disciplinary and is focused on the development of drug carrier systems to facilitate the delivery of drugs and vaccines, providing practical solutions for current healthcare problems.
Hear from Dr. Justin Richner and Dr Yvonne Perrie, leading experts on mRNA Vaccine Therapies in the fields of Cancer Immunotherapy and Infectious Diseases. .
If you are able to attend the event in person: Click here to RSVP
Or,
if you would like to join our Livestream: Click Here to RSVP for the Webinar
Date: Wednesday, April 24, 2019
Time: 13:00-15:00 GMT+1/ 8:00 AM EST /5:00 AM PST
We hope to have you join!
Thousands of compounds may be potential candidates for development as a medical treatment. Rapidly prepare low-volume nanoparticle formulations with the push of a button on the Spark™ or learn how Formulation Solutions can help with proof-of-concept nanoparticle formulations. Nanomedicine is playing a key role in pharmaceutical discovery, largely in the form of nanoparticle-based delivery systems for drugs.
After early testing, only a small number of compounds look promising and call for further study. In this stage, optimizing a wide range of nanomedicine formulations with the NanoAssemblr® Benchtop or
the Blaze™
depending on your volumes to allow you to gather the data on the effectiveness, required dosing and safety of a new therapy.
Develop nanoparticle drugs for clinical evaluation and to support clinical development for their commercialization. Scalable manufacturing is a significant challenge to making revolutionary medicine and Formulation Solutions is ready to assist you in your nanoparticle manufacturing process development. PNI provides a custom Clinical Solution for development and commercial supply.
Get Started
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Technology
Our technology provides a seamless path forward to larger experimental studies, all the way to the clinic: low volume prototype formulations are easily scaled-up using larger instruments of the NanoAssemblr® family, which provides microfluidic mixing and manufacturing of nanoparticles.
Areas of Interest
Nanomedicines span many areas of interest. Explore resourceslike papers, application notes, scientific posters, webinars and more to see how nanotechnology is transforming medicine.
over
70%
of top pharmaceutical companies work with PNI
200+
instruments are installed
worldwide
80+
biopharmaceutical labs use NanoAssemblr® instruments for nanomedicine
drug development
Innovations that accelerate the drug development journey and enable the production of more sophisticated and powerful nanomedicines is our passion. We don’t do it alone, we pursue strategic collaborations that enable researchers to move quickly
in the drug development process. Contact our Business Development Team.
PNI Feature in BioWorld
"As we bite off different problems and succeed on those, we can leverage those technologies," CEO Taylor explains. "We like to think that we're democratizing and lowering the barrier for people to get into these important technologies."
Evonik Collaboration
PNI announces a manufacturing collaboration agreement with Evonik for the tech transfer of the NanoAssemblr® system to Evonik Canada for late-stage clinical research.
License Agreement with Entos Pharmaceuticals
Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines.
Upcoming Events See All
April 29 -
May 03
2019
The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
As the leading American conference focusing solely on gene and cell therapy, ASGCT’s annual meeting brings together over 2,500 professionals including scientists, physicians, and patient advocates.
April 30 -
May 03
2019
CPhI North America
For nearly 30 years, CPhI has organized the world’s most influential pharmaceutical events. Several annual gatherings comprise our iconic worldwide portfolio, but it’s CPhI North America that has become the critical link in a global chain connecting motivated buyers w...
May
20 - 24
2019
Tides: Oligonucleotides and Peptide Therapeutics
TIDES offers separate tracks covering the latest oligonucleotide and peptide development strategies from discovery, nonclinical, clinical and CMC to late-stage development and commercialization.
Resource Center
Publication - Summary
April 04, 2019
The Journal of Neuroscience
PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease
Read MorePublication - Summary
February 07, 2019
Nano Research
Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...
Read MoreApplication Note
January 16, 2019
mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials
Read More
Publication - Summary
September 24, 2018
Nucleic Acid Therapeutics
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Read MorePoster
July 01, 2018
Publication - Summary
February 27, 2018
Cell Reports
A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
Read MoreStay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
MENU
